These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15984185)

  • 1. [Tolcapone treatment of late stages of Parkinson's disease].
    Fedorova NV; Chigir' IP; Krivonos OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(6):31-4. PubMed ID: 15984185
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tolcapone in the management of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolcapone improves sleep in patients with advanced Parkinson's disease (PD).
    Ebersbach G; Hahn K; Lorrain M; Storch A
    Arch Gerontol Geriatr; 2010; 51(3):e125-8. PubMed ID: 20381177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of tolcapone in fluctuating Parkinson's disease.
    Stocchi F; De Pandis MF
    Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tolcapone in the treatment of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone].
    Avila A; Kulisevsky J
    Neurologia; 1998; 13 Suppl 1():66-71. PubMed ID: 9859687
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
    Agid Y; Destée A; Durif F; Montastruc JL; Pollak P
    Lancet; 1997 Sep; 350(9079):712-3. PubMed ID: 9291909
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial.
    Sethi K; Factor S; Watts R
    CNS Spectr; 2010 Jan; 15(1):27-32. PubMed ID: 20394182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience of tolcapone in advanced Parkinson's disease.
    Canesi M; Zecchinelli AL; Pezzoli G; Antonini A
    Neurol Sci; 2008 Dec; 29 Suppl 5():S380-2. PubMed ID: 19381768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 14. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
    Dupont E; Burgunder JM; Findley LJ; Olsson JE; Dorflinger E
    Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advances in Parkinson disease].
    Litvan I
    Rev Neurol; 1999 Jul 16-31; 29(2):139-45. PubMed ID: 10528328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment for Parkinson's disease.
    J R Soc Health; 1997 Jun; 117(3):179. PubMed ID: 9195833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.